Abstract 253P
Background
Nonepithelial ovarian cancers constitute about 10 % of all ovarian cancers. They are divided into sex-cord stromal tumours (SCST) and germ cell tumours (GCT). The Aim is to report the experience at National Centre for Cancer Care and Research (NCCCR) in Qatar.
Methods
This is a retrospective study reviewing records of all patients who presented with a histopathologically diagnosed ovarian SCST and GCT at NCCCR between January 2010 and December 2016. Clinical data including age, stage at diagnosis, histopathology, treatment modalities, disease recurrence and status at last follow up was extracted.
Results
A Total of 25 women with Non Epithelial Ovarian Tumours were identified. 13 women were diagnosed with Ovarian SCST. 12 had granulosa cell tumour , 1 with steroid cell tumour and none of them had Sertoli-Leydig cell tumor. Median age at presentation was 43 years (Range 16-58). 12 patients (92 %) had stage I and 1 patient (8 %) had Stage III. 9 patients had TAH + BSO . 4 patients had conservative surgery without hysterectomy. 2 patients received Adjuvant chemotherapy .4 patients had recurrence. The 5 years Overall Survival (OS) was 100% and the 5 years Event Free Survival (EFS) was 69% with P value of 0.02.
GCT was diagnosed in 12 women. The median age at presentation was 24 years (Range 16 – 44). 7 patients (59 %) had teratoma, 4 patients (33 %) had Dysgerminoma and 1 patient had Yolk sac tumour (8 %). 9 patients ( 75 % ) had Stage 1, 2 patients had Stage 2 ( 17 % ) and 1 patient ( 8 % ) had Stage 4 disease .6 patients ( 50 % ) underwent U/L Oopherectomy .5 patients ( 42 % ) underwent U/L salpingoOopherctomy and Chemotherapy( BEP ) .1 pt. ( 8 % ) with Stage IV disease received only chemotherapy. There was 1 recurrence in the Retroperitoneal LNs in patient with Stage 2 disease. 5 years OS was 100 % and 5 years EFS was 83 % with P value of 0.14.
Conclusions
Survival in our study of SCST was excellent with all patients alive and disease free at last follow up. We recommend Complete Surgery (TAH + BSO) particularly if high grade, Stage 1C and above or completed child bearing to minimize recurrence.
GCTs have very good prognosis in all stages and even in recurrence. Fertility Sparing Surgery is appropriate for all patients with Stage 1 and most of patients with Stage 2 disease who desire fertility preservation.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
24P - The Pink Vans: Bringing cancer screening closer to home
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
25P - Identification of gene mutations in patients with breast cancer in a region located in the southeast of the European part of Russia
Presenter: Alexander Sultanbaev
Session: e-Poster Display Session
26P - Body mass index and clinical outcomes in Egyptian women with breast cancer: A multi-institutional study
Presenter: Amrou Mamdouh Abdeen Shaaban
Session: e-Poster Display Session
27P - Breast cancer primary site and laterality as predictive factors of prognosis: SEER based analysis for survival
Presenter: Eman Zin Eldin
Session: e-Poster Display Session
28P - Breast cancer care services at Nilai Medical Centre: A Malaysian experience
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
29P - Factors affecting breast self-examination (BSE) behaviour among female high school students in Denpasar City, Bali
Presenter: Cindy Trisina
Session: e-Poster Display Session
30P - Male breast cancer: A rural based peripheral cancer center experience
Presenter: SACHIN KHANDELWAL
Session: e-Poster Display Session
31P - The prognostic value of pre-treatment peripheral neutrophil-lymphocyte-ratio (NLR) and its correlation with mutant p53 expression in Indonesian triple negative breast cancer patients
Presenter: Rosita Purwanto
Session: e-Poster Display Session
32P - Clinicopathologic features and prognostic factors in male breast cancer: A single centre experience
Presenter: Izzet Dogan
Session: e-Poster Display Session
33P - FDG-PET predictivity of pathological axillary nodal status in carcinoma breast-upfront and post-neoadjuvant chemotherapy (NACT) setting
Presenter: Krithikaa Sekar
Session: e-Poster Display Session